Full Press Release Details
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update.
ARGX
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
Key Takeaway: argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
Price reaction · baseline $551.71 (2024-10-30 close) · hit after-hours · 1 other ARGX headline(s) in the window, move may be shared
day 0 close
+6.3%
day 1
+8%
day 3 · peak
+9.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis